LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Brief: Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For Lp-184 In Advanced Solid Tumors
Brief: Lantern Pharma Receives Ind Clearance From FDA Enabling Phase 1 Initiation For Drug Candidate Lp-284 In Non-Hodgkin’S Lymphomas
Brief: Lantern Pharma To Present Data Highlighting The Anti-Tumor Potency Of Drug Candidate Lp-284
Brief: Lantern Pharma Expands AI Capabilities Of RADR Platform To Accelerate Clinical Development Of Immune Checkpoint Inhibitors
Brief: Lantern Pharma Receives Notice Of US Patent Allowance For Drug Candidate LP-184 For Treatment Of Rare Pediatric Brain Cancer ATRT
Lantern Pharma Inc reports results for the quarter ended in June - Earnings Summary
Lantern Pharma Inc expected to post a loss of 43 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Precision Optics, Tesla, airline stocks
U.S. STOCKS ON THE MOVE-Lantern Pharma, Disc Medicine, Cybersecurity firms
Brief: Lantern Pharma Receives FDA Clearance Of IND Application For LP-184
Lantern Pharma up on FDA nod to begin early-stage study on cancer therapy
Brief: Lantern Pharma Leverages AI Platform, RADR, To Develop Breakthrough ADCS In Collaboration With Bielefeld University
Lantern Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Lantern Pharma Reports First Quarter 2023 Financial Results
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Lantern Pharma Receives Notice Of Allowance For Composition Of Matter Patent Covering Drug Candidate Lp-284
Brief: Lantern Pharma Announces First Patient Dosed In Phase 2 Study, Harmonic, For Lp-300 In Never Smokers With Advanced Non-Small Cell Lung Cancer
Lantern Pharma Inc reports results for the quarter ended in December - Earnings Summary